Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction

References

• Suwaidi J. A., Hamasaki S., Higano S. T., Nishimura R. A., Holmes D. R Jr., Lerman A. Long‐term follow‐up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948–54
   PubMed Web of Science ®Google Scholar
• Moncada S., Korbut R., Bunting S., Vane J. R. Prostacyclin is a circulating hormone. Nature 1978; 273: 767–8
   PubMed Web of Science ®Google Scholar
• Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium‐derived relaxing factor. Nature 1987; 327: 524–6
   PubMed Web of Science ®Google Scholar
• Stupack D. G., Cheresh D. A. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64: 207–38
   PubMed Web of Science ®Google Scholar
• Busse R., Fleming I. Regulation of NO synthesis in endothelial cells. Kidney Blood Press Res 1998; 21: 264–6
   Google Scholar
• Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1–12
   PubMed Web of Science ®Google Scholar
• Oelze M., Mollnau H., Hoffmann N., Warnholtz A., Bodenschatz M., Smolenski A., et al. Vasodilator‐stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000; 87: 999–1005
   PubMed Web of Science ®Google Scholar
• Myers P. R., Minor R. L Jr., Guerra R Jr., Bates J. N., Harrison D. G. Vasorelaxant properties of the endothelium‐derived relaxing factor more closely resemble S‐nitrosocysteine than nitric oxide. Nature 1990; 345: 161–3
   PubMed Web of Science ®Google Scholar
• Radomski M. W., Palmer R. M., Moncada S. The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639–46
   PubMed Web of Science ®Google Scholar
• Garg U. C., Hassid A. Nitric oxide‐generating vasodilators and 8‐bromo‐cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774–7
   PubMed Web of Science ®Google Scholar
• Gryglewski R. J., Moncada S., Palmer R. M. Bioassay of prostacyclin and endothelium‐derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 1986; 87: 685–94
   PubMed Web of Science ®Google Scholar
• Beckman J. S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996; 9: 836–44
   PubMed Web of Science ®Google Scholar
• Beckman J. S., Koppenol W. H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424–37
   PubMed Web of Science ®Google Scholar
• Zou M. H., Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett 1996; 382: 101–4
   PubMed Web of Science ®Google Scholar
• Zou M. H., Shi C., Cohen R. A. Oxidation of the zinc‐thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109: 817–26
   PubMed Web of Science ®Google Scholar
• Kuzkaya N., Weissmann N., Harrison D. G., Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric‐oxide synthase. J Biol Chem 2003; 278: 22546–54
   PubMed Web of Science ®Google Scholar
• Zeiher A. M., Drexler H., Wollschlager H., Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391–401
   PubMed Web of Science ®Google Scholar
• Zeiher A. M., Drexler H., Wollschlager H., Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984–92
   PubMed Web of Science ®Google Scholar
• Kahler J., Ewert A., Weckmuller J., Stobbe S., Mittmann C., Koster R., et al. Oxidative stress increases endothelin‐1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 2001; 38: 49–57
   PubMed Web of Science ®Google Scholar
• Kahler J., Mendel S., Weckmuller J., Orzechowski H. D., Mittmann C., Koster R., et al. Oxidative stress increases synthesis of big endothelin‐1 by activation of the endothelin‐1 promoter. J Mol Cell Cardiol 2000; 32: 1429–37
   PubMed Web of Science ®Google Scholar
• Lerman A., Holmes D. R Jr., Bell M. R., Garratt K. N., Nishimura R. A., Burnett J. C Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92: 2426–31
   PubMed Web of Science ®Google Scholar
• Celermajer D. S., Sorensen K. E., Gooch V. M., Spiegelhalter D. J., Miller O. I., Sullivan I. D., et al. Non‐invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5
   PubMed Web of Science ®Google Scholar
• Gokce N., Keaney J. F Jr., Hunter L. M., Watkins M. T., Menzoian J. O., Vita J. A. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567–72
   PubMed Web of Science ®Google Scholar
• Gokce N., Keaney J. F Jr., Hunter L. M., Watkins M. T., Nedeljkovic Z. S., Menzoian J. O., et al. Predictive value of noninvasively determined endothelial dysfunction for long‐term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769–75
   PubMed Web of Science ®Google Scholar
• Anderson T. J., Uehata A., Gerhard M. D., Meredith I. T., Knab S., Delagrange D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235–41
   PubMed Web of Science ®Google Scholar
• Warnholtz A., Ostad M. A., Heitzer T., Thuneke F., Frohlich M., Tschentscher P., et al. AT1‐receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Atherosclerosis 2007; 194: 439–45
   PubMedGoogle Scholar
• Bonetti P. O., Pumper G. M., Higano S. T., Holmes D. R Jr., Kuvin J. T., Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137–41
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Dawber T. R., McGee D. L. Perspectives on systolic hypertension. The Framingham study. Circulation 1980; 61: 1179–82
   PubMed Web of Science ®Google Scholar
• Millasseau S. C., Kelly R. P., Ritter J. M., Chowienczyk P. J. Determination of age‐related increases in large artery stiffness by digital pulse contour analysis. Clin Sci (Lond) 2002; 103: 371–7
   PubMed Web of Science ®Google Scholar
• Hayward C. S., Kraidly M., Webb C. M., Collins P. Assessment of endothelial function using peripheral waveform analysis: a clinical application. J Am Coll Cardiol 2002; 40: 521–8
   PubMedGoogle Scholar
• Otto M. E., Svatikova A., Barretto R. B., Santos S., Hoffmann M., Khandheria B., et al. Early morning attenuation of endothelial function in healthy humans. Circulation 2004; 109: 2507–10
   PubMed Web of Science ®Google Scholar
• Plotnick G. D., Corretti M. C., Vogel R. A. Effect of antioxidant vitamins on the transient impairment of endothelium‐dependent brachial artery vasoactivity following a single high‐fat meal. JAMA 1997; 278: 1682–6
   PubMed Web of Science ®Google Scholar
• Title L. Regarding ‘Endothelium‐dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia’. J Vasc Surg 1999; 29: 942–3
   Google Scholar
• Jarvisalo M. J., Jartti L., Marniemi J., Ronnemaa T., Viikari J. S., Lehtimaki T., et al. Determinants of short‐term variation in arterial flow‐mediated dilatation in healthy young men. Clin Sci (Lond) 2006; 110: 475–82
   Google Scholar
• Duffy S. J., Gokce N., Holbrook M., Hunter L. M., Biegelsen E. S., Huang A., et al. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol 2001; 280: H528–34
   Web of Science ®Google Scholar
• Levine G. N., Frei B., Koulouris S. N., Gerhard M. D., Keaney J. F Jr., Vita J. A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93: 1107–13
   PubMed Web of Science ®Google Scholar
• Heitzer T., Just H., Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996; 94: 6–9
   PubMed Web of Science ®Google Scholar
• Ting H. H., Timimi F. K., Boles K. S., Creager S. J., Ganz P., Creager M. A. Vitamin C improves endothelium‐dependent vasodilation in patients with non‐insulin‐dependent diabetes mellitus. J Clin Invest 1996; 97: 22–8
   PubMed Web of Science ®Google Scholar
• Munzel T., Genth‐Zotz S., Hink U. Targeting heme‐oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?. Hypertension 2007; 49: 974–6
   Google Scholar
• Bastian N. R., Hibbs J. B Jr. Assembly and regulation of NADPH oxidase and nitric oxide synthase. Curr Opin Immunol 1994; 6: 131–9
   PubMed Web of Science ®Google Scholar
• Griendling K. K., Sorescu D., Ushio‐Fukai M. NADPH oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494–501
   PubMed Web of Science ®Google Scholar
• Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J. H., Skatchkov M., et al. Increased NADH‐oxidase‐mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin‐angiotensin system. Circulation 1999; 99: 2027–33
   PubMed Web of Science ®Google Scholar
• Guzik T. J., West N. E., Black E., McDonald D., Ratnatunga C., Pillai R., et al. Vascular superoxide production by NADPH oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85–90
   PubMed Web of Science ®Google Scholar
• Sorescu D., Weiss D., Lassegue B., Clempus R. E., Szocs K., Sorescu G. P., et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429–35
   PubMed Web of Science ®Google Scholar
• Ohishi M., Ueda M., Rakugi H., Naruko T., Kojima A., Okamura A., et al. Enhanced expression of angiotensin‐converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15: 1295–302
   Google Scholar
• Diet F., Pratt R. E., Berry G. J., Momose N., Gibbons G. H., Dzau V. J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756–67
   PubMed Web of Science ®Google Scholar
• Schieffer B., Schieffer E., Hilfiker‐Kleiner D., Hilfiker A., Kovanen P. T., Kaartinen M., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372–8
   PubMed Web of Science ®Google Scholar
• Nickenig G., Baumer A. T., Temur Y., Kebben D., Jockenhovel F., Bohm M. Statin‐sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131–4
   PubMed Web of Science ®Google Scholar
• Fukui T., Ishizaka N., Rajagopalan S., Laursen J. B., Capers Q. T., Taylor W. R., et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45–51
   PubMed Web of Science ®Google Scholar
• Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B. A., Griendling K. K., et al. Angiotensin II‐mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916–23
   PubMed Web of Science ®Google Scholar
• Morawietz H., Weber M., Rueckschloss U., Lauer N., Hacker A., Kojda G. Upregulation of vascular NADPH oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun 2001; 285: 1130–5
   PubMed Web of Science ®Google Scholar
• Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14–22
   PubMed Web of Science ®Google Scholar
• Landmesser U., Dikalov S., Price S. R., McCann L., Fukai T., Holland S. M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201–9
   PubMed Web of Science ®Google Scholar
• Ohara Y., Peterson T. E., Harrison D. G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546–51
   PubMed Web of Science ®Google Scholar
• White C. R., Darley‐Usmar V., Berrington W. R., McAdams M., Gore J. Z., Thompson J. A., et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 1996; 93: 8745–9
   PubMed Web of Science ®Google Scholar
• Cardillo C., Kilcoyne C. M., Cannon R. O 3rd., Quyyumi A. A., Panza J. A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30: 57–63
   PubMed Web of Science ®Google Scholar
• Butler R., Morris A. D., Belch J. J., Hill A., Struthers A. D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746–51
   PubMed Web of Science ®Google Scholar
• O'Driscoll J. G., Green D. J., Rankin J. M., Taylor R. R. Nitric oxide‐dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol 1999; 26: 779–83
   PubMedGoogle Scholar
• Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., Inoue M. Does superoxide underlie the pathogenesis of hypertension?. Proc Natl Acad Sci U S A 1991; 88: 10045–8
   PubMed Web of Science ®Google Scholar
• Cleland J. G., Coletta A. P., Clark A. L. Clinical trials update from the Heart Failure Society of America meeting: FIX‐CHF‐4, selective cardiac myosin activator and OPT‐CHF. Eur J Heart Fail 2006; 8: 764–6
   PubMed Web of Science ®Google Scholar
• Pritchard K. A Jr., Groszek L., Smalley D. M., Sessa W. C., Wu M., Villalon P., et al. Native low‐density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510–8
   PubMed Web of Science ®Google Scholar
• Vergnani L., Hatrik S., Ricci F., Passaro A., Manzoli N., Zuliani G., et al. Effect of native and oxidized low‐density lipoprotein on endothelial nitric oxide and superoxide production : key role of L‐arginine availability. Circulation 2000; 101: 1261–6
   PubMed Web of Science ®Google Scholar
• White C. R., Brock T. A., Chang L. Y., Crapo J., Briscoe P., Ku D., et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A 1994; 91: 1044–8
   PubMed Web of Science ®Google Scholar
• Laursen J. B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B. A., et al. Endothelial regulation of vasomotion in apoE‐deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282–8
   PubMed Web of Science ®Google Scholar
• Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999; 263: 681–4
   PubMed Web of Science ®Google Scholar
• Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708–14
   PubMed Web of Science ®Google Scholar
• Schachinger V., Britten M. B., Zeiher A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long‐term outcome of coronary heart disease. Circulation 2000; 101: 1899–906
   PubMed Web of Science ®Google Scholar
• Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673–8
   PubMed Web of Science ®Google Scholar
• Heitzer T., Baldus S., von Kodolitsch Y., Rudolph V., Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005; 25: 1174–9
   PubMed Web of Science ®Google Scholar
• Perticone F., Ceravolo R., Pujia A., Ventura G., Iacopino S., Scozzafava A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–6
   PubMed Web of Science ®Google Scholar
• Brevetti G., Silvestro A., Di Giacomo S., Bucur R., Di Donato A., Schiano V., et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 2003; 38: 374–9
   PubMed Web of Science ®Google Scholar
• Verma S., Wang C. H., Lonn E., Charbonneau F., Buithieu J., Title L. M., et al. Cross‐sectional evaluation of brachial artery flow‐mediated vasodilation and C‐reactive protein in healthy individuals. Eur Heart J 2004; 25: 1754–60
   PubMed Web of Science ®Google Scholar
• Kathiresan S., Gona P., Larson M. G., Vita J. A., Mitchell G. F., Tofler G. H., et al. Cross‐sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 2006; 113: 938–45
   PubMed Web of Science ®Google Scholar
• Juonala M., Viikari J. S., Alfthan G., Marniemi J., Kahonen M., Taittonen L., et al. Brachial artery flow‐mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007; 116: 1367–73
   PubMed Web of Science ®Google Scholar
• Blann A. D., Woywodt A., Bertolini F., Bull T. M., Buyon J. P., Clancy R. M., et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93: 228–35
   PubMed Web of Science ®Google Scholar
• Rajagopalan S., Somers E. C., Brook R. D., Kehrer C., Pfenninger D., Lewis E., et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677–83
   PubMed Web of Science ®Google Scholar
• Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999–1007
   PubMed Web of Science ®Google Scholar
• Schmidt‐Lucke C., Rossig L., Fichtlscherer S., Vasa M., Britten M., Kamper U., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981–7
   PubMed Web of Science ®Google Scholar
• Dimmeler S., Aicher A., Vasa M., Mildner‐Rihm C., Adler K., Tiemann M., et al. HMG‐CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3‐kinase/Akt pathway. J Clin Invest 2001; 108: 391–7
   PubMed Web of Science ®Google Scholar
• Boulanger C. M., Scoazec A., Ebrahimian T., Henry P., Mathieu E., Tedgui A., et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649–52
   PubMed Web of Science ®Google Scholar
• Boulanger C. M., Amabile N., Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006; 48: 180–6
   PubMed Web of Science ®Google Scholar
• Tramontano A. F., O'Leary J., Black A. D., Muniyappa R., Cutaia M. V., El‐Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho‐kinase pathway. Biochem Biophys Res Commun 2004; 320: 34–8
   PubMed Web of Science ®Google Scholar
• Kerns W., Schwartz L., Blanchard K., Burchiel S., Essayan D., Fung E., et al. Drug‐induced vascular injury—a quest for biomarkers. Toxicol Appl Pharmacol 2005; 203: 62–87
   PubMed Web of Science ®Google Scholar
• Schnabel R., Blankenberg S., Lubos E., Lackner K. J., Rupprecht H. J., Espinola‐Klein C., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2000; 97: e53–9
   Google Scholar
• Cooke J. P. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol 2000; 20: 2032–7
   PubMed Web of Science ®Google Scholar
• Sydow K., Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41–51
   PubMed Web of Science ®Google Scholar
• Deanfield J. E., Halcox J. P., Rabelink T. J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285–95
   PubMed Web of Science ®Google Scholar